Swedish Orphan Biovitrum trades up after launch of rare cap increase

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Follow-ons and Rights issues

Swedish Orphan Biovitrum trades up after launch of rare cap increase

Victoria Thiele
August 23, 2023 09:26 am
Sobi at Campus Solna, Stockholm, Sweden. Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.

Sobi plans to repay debt from an acquisition through a non-underwritten rights issue

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Follow-ons and Rights issuesBank of AmericaDanske BankSwedenSwedish kronaEquity
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
Gift this article